Stockscreener 앱 받기
4.04
0.00%
0.00
X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Universe Pharmaceuticals (NASDAQ: UPC) CEO receives share grants under 2026 equity plan - Stock Titan
[Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress - Yahoo Finance
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now - sharewise.com
Can Encompass Health's Expansion Strategy Make It a Hold for Now? - TradingView
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
[EFFECT] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Perceptive group holds 7.3% of X4 Pharmaceuticals (NASDAQ: XFOR) with exercisable warrants - Stock Titan
This Insider Has Just Sold Shares In X4 Pharmaceuticals - simplywall.st
ANIP Valuation: Does 9.8x Forward P/E Offer Upside? - TradingView
Layoff Tracker: Takeda cuts 4,500, Novartis lays off biomedical research staff - BioSpace
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Biogen buys Apellis (APLS) for $41 cash plus CVR per share - Stock Titan
Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR - Stock Titan
Biogen deal: Apellis (APLS) director’s shares and options cashed out - Stock Titan
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap - Stock Titan
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now - Yahoo Finance
X4 Pharmaceuticals (XFOR) corrects director nominee and expands equity plan - Stock Titan
X4 Pharma CFO Kirske sells $72,820 in common stock - Investing.com
X4 Pharmaceuticals (XFOR) CFO sells shares to cover tax obligation - Stock Titan
[144] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Shareholders at X4 Pharmaceuticals (NASDAQ: XFOR) approve equity plan - Stock Titan
5 Unrivaled Penny Stocks to Buy Now - Insider Monkey
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
XFOR (X4 Pharmaceuticals) beats Q1 2026 EPS estimates by 21.6 percent, shares climb 3 percent.Collaborative Trading Signals - newser.com
How X4 Pharmaceuticals (XFOR) is positioning for the next five years (Bearish Sentiment) 2026-05-08Shared Momentum Picks - newser.com
Major holder Artal group converts LXRX (LXRX) Series B preferred into 20.4M common shares - Stock Titan
Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
CapEx per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
EBIT per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
X4 pharmaceuticals incmay offer up to $300 million of common stock, preferred stock, debt securities, warrants, and/or unitsSEC filing - marketscreener.com
X4 Pharmaceuticals IncMay Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or UnitsSEC Filing - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) files $300M shelf; $75M ATM with Jefferies - Stock Titan
X4 Pharmaceuticals, Inc. Q1 2026 Financial Results and Forward-Looking Statements – Quarterly Report Highlights - Minichart
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
X4 Pharmaceuticals: Q1 Earnings Snapshot - KING5.com
X4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI - Quiver Quantitative
EU authorizes first WHIM syndrome treatment as X4 trial nears enrollment - Stock Titan
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
EU approves XOLREMDI as X4 Pharmaceuticals (NASDAQ: XFOR) reports Q1 loss - Stock Titan
X4 Pharmaceuticals Inc (XFOR) - MSN
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA - ACCESS Newswire
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Business Wire
MSN Money - MSN
Processa (PCSA) CAO Wendy Guy buys 1,748 shares in open-market trade - Stock Titan
Seven new Xenon hires get stock awards priced at $56.04 - Stock Titan
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity - The Manila Times
Europe authorizes first drug for patients with relentless hunger - Stock Titan
XFOR Stock Price, Quote & Chart | X4 PHARMACEUTICALS INC (NASDAQ:XFOR) - ChartMill
Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan - Stock Titan
X4 Pharmaceuticals (XFOR) Stock: Directional Bias Review | Q4 2025: Earnings Beat EstimatesCrowd Trend Signals - Newser
$1.9B deal gives Chiesi first oral, on-demand hereditary angioedema treatment - Stock Titan
X4 Pharmaceuticals gets EU approval for WHIM syndrome drug By Investing.com - Investing.com Canada
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - The Manila Times
A rare immune disorder gets its first approved treatment across Europe - Stock Titan
2.98%
1.33%
자본화:
|
볼륨(24시간):